newsfilter
← Earnings
Earnings Releases·

BlossomHill Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss widened to $24.0 million ($1.29/share) from $16.0 million ($6.54/share) in Q3 2025, driven by a $7.3 million increase in R&D expenses and $1.5 million rise in G&A, while cash and cash equivalents grew to $224.9 million following an August 2026 IPO that raised $168.3 million.
  • Management confirmed cash reserves are sufficient to fund operations through Q2 2028, with key milestones scheduled for 2027 including the first patient dosing for the pivotal SOLARA-2 trial (Q1 2027), an IND filing for BH-501284 (Q1 2027), and multiple Phase 1 data updates for BH-30643 and BH-30236.
  • Strategic progress includes FDA alignment on a 50 mg twice-daily Phase 2 dose for BH-30643 and a new Foundation Medicine partnership to develop a companion diagnostic for EGFR C797S resistance, alongside orphan drug designation for BH-30236.
Company
BLOSSOMHILL THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology